drugset / Trial / NCT05176288
Avelumab, Palbociclib and Axitinib in Advanced RCC
NaSingle-groupOpen-labelTreatment
Summary
The aim of this study is to see whether the combination of 3 drugs (axitinib, avelumab and palbociclib) is safe and effective in slowing down the growth of advanced clear cell renal cell carcinoma (ccRCC) in patients that have not received any prior systemic treatment. The names of the study drug involved in this study are/is: * Axitinib * Avelumab * Palbociclib
Timeline
- Start
- 2024-05-31
- Primary completion
- 2026-08-31
- Completion
- 2027-08-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Avelumab | Monoclonal antibody | — | Intravenous |
| Subject | Axitinib | Small molecule | — | Oral |
| Subject | Palbociclib | Small molecule | — | Oral |